Takeda's Approved Blood Cancer Drug Hits Primary Goal In Newly-Diagnosed Patient Settings

Takeda's Approved Blood Cancer Drug Hits Primary Goal In Newly-Diagnosed Patient Settings
  • Takeda Pharmaceutical Co Ltd's TAK Phase 3 PhALLCON trial of Iclusig (ponatinib) met its primary endpoint in newly-diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) patients.
  • The study demonstrated that Iclusig plus reduced-intensity chemotherapy achieved higher rates of minimal residual disease (MRD)-complete negative remission (CR) compared to imatinib. 
  • In the trial, no new safety signals were observed. 
  • Related: Takeda Seeks FDA Approval For Hereditary Angioedema Treatment For Younger Kids.
  • In September, Puma Biotechnology Inc PBYI announced an agreement to license the worldwide research and development and commercial rights to Takeda's alisertib for cancer indications.
  • Alisertib has been tested in metastatic cancers, including breast cancer, small cell lung cancer, head and neck cancer, ovarian cancer, peripheral T cell lymphoma, and acute myeloid leukemia.
  • Price Action: TAK shares are up 1.13% at $13.93 on the last check Thursday.
  • Photo Via Company

Posted In: BriefsBiotechLarge CapNewsPenny StocksHealth CareGeneral